Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence

NCT01824823 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT01824823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01824823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2014
Completion date
December 31, 2020
Enrollment
3 (actual)
Sites
272

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma